Effect of Anti-CD303 Antibodies in Autoimmune Diseases (ANTI-CD303)

University Hospital, Lille

Status: Completed

Conditions: Immune Disease

Treatments: Biological: Monoclonal anti-cd303 antibody

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03370627

2017_23

2017_A02244-49 (Other Identifier)

Details and patient eligibility

About

The pathogenic role of type I interferons (IFNs) in the development of different autoimmune diseases has been extensively described in the literature. Since plasmacytoid dendritic cells (pDCs) are the main source of type I IFNs, there is evidence of the involvement of pDCs in autoimmune diseases. The CD303 surface protein (also called BDCA-2) is specifically expressed by the pDCs.

The hypothesis leading to the realization of this study is to observe, in vitro, an inhibition of the secretion of the type I IFNs by pDCs in the peripheral blood in patients with autoimmune disease, thanks to the action of the anti-CD303 antibody Developed by the LFB Group, which could reduce the inflammatory response and improve patients with autoimmune disease

Enrollment: 138 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study data collection procedures
• Patient followed in the department of internal medicine of CHU Lille
• Patient with one of the following autoimmune disease, defined according to international criteria: systemic lupus erythematosus, systemic sclerosis, Gougerot-Sjögren syndrome and idiopathic thrombocytopenic purpura
• Being socially insured

Exclusion criteria

• Overlapping syndrome with another autoimmune disease
• Age ≤18 years
• Pregnant or nursing women
• People in emergencies
• Person incapable of consent
• Persons deprived of liberty
• Persons without social security cover

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

138 participants in 1 patient group

Patient

Experimental group

Treatment:

Biological: Monoclonal anti-cd303 antibody